908 Devices (MASS) Competitors

908 Devices (NASDAQ:MASS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Do insiders & institutionals believe in MASS or CTKB?

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 27.7% of 908 Devices shares are held by company insiders. Comparatively, 9.6% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts rate MASS or CTKB?

908 Devices currently has a consensus price target of $5.33, suggesting a potential upside of 33.00%. Cytek Biosciences has a consensus price target of $6.42, suggesting a potential upside of 56.50%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytek Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Which has stronger valuation & earnings, MASS or CTKB?

Cytek Biosciences has higher revenue and earnings than 908 Devices. Cytek Biosciences is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$59.63M	2.38	-$36.40M	-$2.10	-1.91
Cytek Biosciences	$200.45M	2.62	-$12.15M	-$0.05	-82.00

Is MASS or CTKB more profitable?

Cytek Biosciences has a net margin of -5.05% compared to 908 Devices' net margin of -109.11%. Cytek Biosciences' return on equity of -2.58% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-109.11%	-24.60%	-19.23%
Cytek Biosciences	-5.05%	-2.58%	-2.05%

Does the MarketBeat Community favor MASS or CTKB?

Cytek Biosciences received 3 more outperform votes than 908 Devices when rated by MarketBeat users. However, 51.35% of users gave 908 Devices an outperform vote while only 45.83% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
908 Devices	Outperform Votes 19 51.35%	Underperform Votes 18 48.65%
Cytek Biosciences	Outperform Votes 22 45.83%	Underperform Votes 26 54.17%

Which has more risk & volatility, MASS or CTKB?

908 Devices has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Does the media refer more to MASS or CTKB?

In the previous week, Cytek Biosciences had 5 more articles in the media than 908 Devices. MarketBeat recorded 8 mentions for Cytek Biosciences and 3 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.83 beat Cytek Biosciences' score of 0.15 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Cytek Biosciences beats 908 Devices on 11 of the 17 factors compared between the two stocks.